Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma:


Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 6 10 2019
medline: 29 9 2020
entrez: 6 10 2019
Statut: ppublish

Résumé

Fibroblast activation protein (FAP), which promotes tumor growth and progression, is overexpressed in cancer-associated fibroblasts of many human epithelial cancers. Because of its low expression in normal organs, FAP is an excellent target for theranostics. In this study, we used radionuclides with relatively long half-lives,

Identifiants

pubmed: 31586001
pii: jnumed.119.233122
doi: 10.2967/jnumed.119.233122
pmc: PMC7198371
doi:

Substances chimiques

Actinium-225 0
Copper Radioisotopes 0
Copper-64 0
Membrane Proteins 0
Radiopharmaceuticals 0
Endopeptidases EC 3.4.-
Serine Endopeptidases EC 3.4.21.-
fibroblast activation protein alpha EC 3.4.21.-
Gelatinases EC 3.4.24.-
Actinium NIK1K0956U

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

563-569

Informations de copyright

© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Références

J Nucl Med. 2018 Sep;59(9):1415-1422
pubmed: 29626119
Clin Cancer Res. 2002 Jun;8(6):1974-83
pubmed: 12060643
J Nucl Med. 2020 Jan;61(1):62-69
pubmed: 31101746
BMC Cancer. 2011 Jun 13;11:245
pubmed: 21668992
Bioconjug Chem. 2000 Jul-Aug;11(4):527-32
pubmed: 10898574
Cancer J. 2015 Jul-Aug;21(4):250-3
pubmed: 26222075
J Nucl Med. 2017 Oct;58(10):1624-1631
pubmed: 28408529
Anal Chem. 2005 Oct 1;77(19):6288-91
pubmed: 16194090
J Nucl Med. 2019 Oct;60(10):1421-1429
pubmed: 30850501
Oncol Lett. 2017 Sep;14(3):2611-2620
pubmed: 28927027
Front Biosci (Landmark Ed). 2010 Jan 01;15(1):166-79
pubmed: 20036813
J Nucl Med. 2019 Mar;60(3):362-368
pubmed: 30042163
J Nucl Med. 2019 Mar;60(3):386-392
pubmed: 30072500
J Nucl Med. 2009 Mar;50(3):401-8
pubmed: 19223424
Cancer Biother Radiopharm. 2013 Nov;28(9):657-64
pubmed: 23789969
J Nucl Med. 2018 Sep;59(9):1423-1429
pubmed: 29626120
Sci Rep. 2016 Feb 17;6:21648
pubmed: 26884312
Br J Cancer. 2013 Sep 17;109(6):1562-9
pubmed: 23942066
Mol Med Rep. 2015 May;11(5):3203-11
pubmed: 25593080
J Nucl Med. 2016 Dec;57(12):1941-1944
pubmed: 27390158
J Nucl Med. 2019 Jun;60(6):801-805
pubmed: 30954939
PLoS One. 2015 Mar 16;10(3):e0116683
pubmed: 25775399
PLoS One. 2018 Apr 18;13(4):e0195802
pubmed: 29668724

Auteurs

Tadashi Watabe (T)

Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan watabe@tracer.med.osaka-u.ac.jp.
Institute for Radiation Sciences, Osaka University, Osaka, Japan.

Yuwei Liu (Y)

Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan.

Kazuko Kaneda-Nakashima (K)

Institute for Radiation Sciences, Osaka University, Osaka, Japan.
Core for Medicine and Science Collaborative Research and Education, Project Research Center for Fundamental Sciences, Graduate School of Science, Osaka University, Osaka, Japan.

Yoshifumi Shirakami (Y)

Institute for Radiation Sciences, Osaka University, Osaka, Japan.

Thomas Lindner (T)

Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.

Kazuhiro Ooe (K)

Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan.
Institute for Radiation Sciences, Osaka University, Osaka, Japan.

Atsushi Toyoshima (A)

Institute for Radiation Sciences, Osaka University, Osaka, Japan.
Core for Medicine and Science Collaborative Research and Education, Project Research Center for Fundamental Sciences, Graduate School of Science, Osaka University, Osaka, Japan.

Kojiro Nagata (K)

Radioisotope Research Center, Institute for Radiation Sciences, Osaka University, Osaka, Japan.

Eku Shimosegawa (E)

Institute for Radiation Sciences, Osaka University, Osaka, Japan.
Department of Molecular Imaging in Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.

Uwe Haberkorn (U)

Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit of Nuclear Medicine, DKFZ, Heidelberg, Germany.
Translational Lung Research Center Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germany.

Clemens Kratochwil (C)

Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.

Atsushi Shinohara (A)

Institute for Radiation Sciences, Osaka University, Osaka, Japan.
Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan; and.

Frederik Giesel (F)

Institute for Radiation Sciences, Osaka University, Osaka, Japan.
Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.

Jun Hatazawa (J)

Institute for Radiation Sciences, Osaka University, Osaka, Japan.
Research Center for Nuclear Physics, Osaka University, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH